177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

PURPOSE: Preliminary data from retrospective analyses and recent data from large randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited data...

Descripción completa

Detalles Bibliográficos
Autores principales: Khreish, Fadi, Ghazal, Zaidoon, Marlowe, Robert J., Rosar, Florian, Sabet, Amir, Maus, Stephan, Linxweiler, Johannes, Bartholomä, Mark, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803625/
https://www.ncbi.nlm.nih.gov/pubmed/34494131
http://dx.doi.org/10.1007/s00259-021-05525-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803625/
https://www.ncbi.nlm.nih.gov/pubmed/34494131
http://dx.doi.org/10.1007/s00259-021-05525-7

Ejemplares similares